Peter J. Wedlund

The CYP2D6 Poor Metabolizer Phenotype May Be Associated With Risperidone Adverse Drug Reactions and Discontinuation

José de León, Margaret T. Susce, Run-Mei Pan et al. · The Journal of Clinical Psychiatry · 2005 · 317 citations

Extension of a Pilot Study: Impact From the Cytochrome P450 2D6 Polymorphism on Outcome and Costs Associated With Severe Mental Illness

Wen Hwei Chou, Fengxiang Yan, José de León et al. · Journal of Clinical Psychopharmacology · 2000 · 225 citations

Psychiatric Evaluation, Psychiatric Disorders, Pharmacotherapy +23

The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: Screening costs and influence on clinical outcomes in psychiatry*

Shuqing Chen, Wen-Hwei Chou, Robert A. Blouin et al. · Clinical Pharmacology & Therapeutics · 1996 · 152 citations

Comparison of Two CYP2D6 Genotyping Methods and Assessment of Genotype-Phenotype Relationships

Wen-Hwei Chou, Fengxiang Yan, Doris Robbins‐Weilert et al. · Clinical Chemistry · 2003 · 120 citations

A Pilot Study on Risperidone Metabolism

Jayme A. Bork, Thea Rogers, Peter J. Wedlund et al. · The Journal of Clinical Psychiatry · 1999 · 118 citations

Molecular Pharmacology, Plasma Risperidone Levels, Health Sciences +15